Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer

Molecular Genetics and Genomics

Volumn 287, Issue 9, 2012, Pages 755-764

  Szkandera, Joanna ^a   Absenger, Gudrun ^a   Dandachi, Nadia ^a   Regitnig, Peter ^a   Lax, Sigurd ^b   Stotz, Michael ^a   Samonigg, Hellmut ^a   Renner, Wilfried ^a   Gerger, Armin ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b General Hospital Graz West   (Austria)

Author keywords

Anthracycline; Breast cancer; Germline polymorphisms; Neoadjuvant chemotherapy

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; ESTROGEN RECEPTOR; INTERLEUKIN 6; PACLITAXEL; PROGESTERONE RECEPTOR; PROTEIN P53; TOLL LIKE RECEPTOR 4; XRCC1 PROTEIN;

AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CODON; DISEASE FREE SURVIVAL; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GERM LINE; GERMLINE POLYMORPHISM; HUMAN; HUMAN TISSUE; INTERLEUKIN 6 GENE; MAJOR CLINICAL STUDY; NAD(P)H DEHYDROGENASE (QUINONE) 1 GENE; OVERALL SURVIVAL; PHARMACOGENETICS; PREDICTIVE VALUE; PRIORITY JOURNAL; TOLL LIKE RECEPTOR 4 GENE; TUMOR PROTEIN 53 GENE; X RAY CROSS COMPLEMENTING GROUP 1 GENE;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; OXIDATIVE STRESS; POLYMORPHISM, GENETIC; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84867397162     PISSN: 16174615     EISSN: 16174623     Source Type: Journal    
DOI: 10.1007/s00438-012-0715-7     Document Type: Article

References (52)

1. Allegra JC, Lippman ME, Thompson EB, Simon R, Barlock A, Green L, Huff KK, Do HM, Aitken SC, Warren R (1978) Association between steroid hormone receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. Cancer Treat Rep 62:1281-1286
2. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, André F, Delaloge S, Tursz T, Kroemer G, Zitvogel L (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13:1050-1059. doi:10.1038/nm1622
3. Archer CD, Parton M, Smith IE, Ellis PA, Salter J, Ashley S, Gui G, Sacks N, Ebbs SR, Allum W, Nasiri N, Dowsett M (2003) Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer. Br J Cancer 89:1035-1041. doi: 10.1038/sj.bjc.6601173
4. Bergmann C, Bachmann HS, Bankfalvi A, Lotfi R, Pütter C, Wild CA, Schuler PJ, Greve J, Hoffmann TK, Lang S, Scherag A, Lehnerdt GF (2011) Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile in head and neck squamous cell carcinomas. J Transl Med 9:139. doi:10.1186/1479- 5876-9-139
5. Bewick MA, Conlon MS, Lafrenie RM (2006) Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer. J Clin Oncol 24:5645-5651. doi:10.1200/JCO.2006.05.9923
6. Burcombe RJ, Makris A, Richman PI, Daley FM, Noble S, Pittam M, Wright D, Allen SA, Dove J, Wilson GD (2005) Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 92:147-155. doi:10.1038/sj.bjc.6602256
7. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, PerouCM(2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329-2334. doi:10.1158/1078-0432.CCR-06-1109
8. Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P (1993) Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 16:223-228
9. Damin AP, Frazzon AP, Damin DC, Roehe A, Hermes V, Zettler C, Alexandre CO (2006) Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk. Cancer Detect Prev 30:523-529. doi:10.1016/j.cdp.2006.09.007
10. DeMichele A, Gray R, Horn M, Chen J, Aplenc R, Vaughan WP, Tallman MS (2009) Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer. Cancer Res 69:4184-4191. doi:10.1158/0008-5472.CAN-08-2989
11. Dickson RB, Lippman ME (1988) Control of human breast cancer by estrogen, growth factors, and oncogenes. Cancer Treat Res 40:119-165
12. Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357-365. doi:10.1038/ng1093
13. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) (2010) AJCC cancer staging manual, 7th edn. Springer, New York, p 439
14. Ellis PA, Smith IE, McCarthy K, Detre S, Salter J, Dowsett M (1997) Preoperative chemotherapy induces apoptosis in early breast cancer. Lancet 349:849
15. Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, Syrjäkoski K, Kallioniemi A, Kilpivaara O, Mannermaa A, Kosma VM, Uusitupa M, Eskelinen M, Kataja V, Aittomäki K, von Smitten K, Heikkilä P, Lukas J, Holli K, Bartkova J, Blomqvist C, Bartek J, Nevanlinna H (2008) NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 40:844-853. doi:10.1038/ng.155
16. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB Jr, Hoehn JL, Lees AW, Dimitrov NV, Bear HD (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685
17. Giannitrapani L, Soresi M, Giacalone A, Campagna ME, Marasà M, Cervello M, Marasà S, Montalto G (2011) IL-6 -174G/C polymorphism and IL-6 serum levels in patients with liver cirrhosis and hepatocellular carcinoma. OMICS 15:183-186. doi:10.1089/omi.2010.0093
18. Han JY, Lee GK, Jang DH, Lee SY, Lee JS (2008) Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer 113:799-807. doi:10.1002/cncr.23668
19. Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, Belau A, Khandan F, Hauschild M, Thomssen C, Högel B, Darb-Esfahani S, Mehta K, Loibl S (2010) Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 124:133-140. doi:10.1007/s10549-010- 1103-9
20. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90. doi: 10.3322/caac.20107
21. Johnstone RW, Ruefli AA, Lowe SW (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108:153-164. doi:10.1016/S0092-8674-00625-6
22. Kaufmann M, Klinga K, Runnebaum B, Kubli F (1980) In vitro adriamycin sensitivity test and hormonal receptors in primary breast cancer. Eur J Cancer 16:1609-1613
23. Kim K, Kang SB, Chung HH, Kim JW, Park NH, Song YS (2008) XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms are associated with response to platinumbased neoadjuvant chemotherapy in cervical cancer. Gynecol Oncol 111:509-515. doi:10.1016/j.ygyno.2008.08.034
24. Kim JG, Chae YS, Sohn SK, Moon JH, Ryoo HM, Bae SH, Kum Y, Jeon SW, Lim KH, Kang BM, Park IJ, Choi GS, Jun SH (2009) Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin. Cancer Chemother Pharmacol 64:953-960. doi:10.1007/s00280-009-0947- 3
25. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469
26. Lee PH, Shatkay H (2008) F-SNP: computationally predicted functional SNPs for disease association studies. Nucleic Acids Res 36:D820-D824. doi:10.1093/nar/gkm904
27. Lee PH, Shatkay H (2009) An integrative scoring system for ranking SNPs by their potential deleterious effects. Bioinformatics 25:1048-1055. doi:10.1093/bioformatics/btp103
28. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323-331
29. Lippman ME, Allegra JC, Thompson EB, Simon R, Barlock A, Green L, Huff KK, Do HM, Aitken SC, Warren R (1978) The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 298: 1223-1228
30. Loizidou MA, Michael T, Neuhausen SL, Newbold RF, Marcou Y, Kakouri E, Daniel M, Papadopoulos P, Malas S, Kyriacou K, Hadjisavvas A (2008) Genetic polymorphisms in the DNA repair genes XRCC1, XRCC2 and XRCC3 and risk of breast cancer in Cyprus. Breast Cancer Res Treat 112:575-579. doi:10.1007/s10549-007- 9881-4
31. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV (1987) Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 7:961-963. doi:10.1128/MCB.7.2.961
32. Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, Schofield A, Heys SD (2003) A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 12:320-327
33. Petit T, Wilt M, Velten M, Millon R, Rodier JF, Borel C, Mors R, Haegelé P, Eber M, Ghnassia JP (2004) Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 40:205-211. doi:10.1016/s0959-8049-00675-0
34. Pim D, Banks L (2004) p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108:196-199. doi:10.1002/ijc.11548
35. Remmele W (1997) Pathologie, vol 4, 2nd edn. Springer, Berlin, p 259
36. Sakamuro D, Sabbatini P, White E, Prendergast GC (1997) The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 15:887-898
37. Shen MR, Jones IM, Mohrenweiser H (1998) Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 58:604-608
38. Shiraishi K, Kohno T, Tanai C, Goto Y, Kuchiba A, Yamamoto S, Tsuta K, Nokihara H, Yamamoto N, Sekine I, Ohe Y, Tamura T, Yokota J, Kunitoh H (2010) Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 28:4945-4952. doi:10.1200/JCO.2010.30.5334
39. Siegel D, Anwar A, Winski SL, Kepa JK, Zolman KL, Ross D (2001) Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Mol Pharmacol 59:263-268
40. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L (1998) Role of a p53 polymorphism in the development of human papillomavirusassociated cancer. Nature 393:229-234. doi:10.1038/30400
41. Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiante G, Attard M, Hiller L, Farrell PJ, Smith P, Lu X, Crook T (2004) Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23:3328-3337. doi:10.1038/sj.onc.1207428
42. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G (1999) Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19:1092-1100
43. Tiezzi DG, Andrade JM, Ribeiro-Silva A, Zola FE, Marana HR, Tiezzi MG (2007) HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. BMC Cancer 7:36. doi:10.1186/1471-2407-7-36
44. Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J, Ristimäki A, von Smitten K, Aittomäki K, Heikkilä P, Blomqvist C, Nevanlinna H (2005) Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 11:5098-5103. doi:10.1158/1078-0432.CCR- 05-0173
45. Toyama T, Zhang Z, Nishio M, Hamaguchi M, Kondo N, Iwase H, Iwata H, Takahashi S, Yamashita H, Fujii Y (2007) Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res 9:R34. doi: 10.1186/bcr1682
46. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408:307-310. doi:10.1038/35042675
47. Walker KK, Levine AJ (1996) Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci USA 93:15335-15340
48. Windsor RE, Strauss SJ, Kallis C, Wood NE, Whelan JS (2012) Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study. Cancer 118:1856-1867. doi:10.1002/cncr.26472
49. Wolff AC, Davidson NE (2000) Primary systemic therapy in operable breast cancer. J Clin Oncol 18:1558-1569
50. Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan Z, Lin B, Lu Y, Xie Y (2005) p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 11:7328-7333. doi:10.1158/1078-0432.CCR-05-0507
51. Yi SY, Lee WJ (2006) A p53 genetic polymorphism of gastric cancer: difference between early gastric cancer and advanced gastric cancer. World J Gastroenterol 12:6536-6539
52. Zhang F, Yang Y, Smith T, Kau SW, McConathy JM, Esteva FJ, Kuerer HM, Symmans WF, Buzdar AU, Hortobagyi GN, Pusztai L (2003) Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer 97:1758-1765. doi:10.1002/cncr.11245